Please login to the form below

Not currently logged in
Email:
Password:

MorphoSys appoints Dr Markus Enzelberger as CSO

He succeeds Dr Marlies Sproll who resigns

Markus EnzelbergerGerman biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation.

Sproll will remain with the company on a part-time basis as a special advisor to chief executive officer Dr Simon Moroney, however Dr Enzelberger, who joined MorphySys in 2002, has served as its interim CSO since April this year.

Dr Enzelberger has served in various capacities at MorphoSys including senior vice president, discovery, alliances and technologies, taking responsibility for the drug discovery activities for proprietary and partnered programmes.

Dr Gerald Moller, supervisory board chairman, MorphoSys, said: “Dr Enzelberger is the perfect person to take over the CSO role at MorphoSys on a permanent basis.

“Drawing on his vast scientific expertise and experience in the management of antibody technology, research and discovery, he will continue to drive the group’s early-stage research activities with the goal of fuelling the company’s R&D pipeline with novel drug candidates in oncology and immunology.”

9th November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...